This new paper dedicated to hiPSC expansion with the C-Stem™ technology platform shows that: hiPSCs seeded in C-Stem™-generated capsules self-organize into in vivo-like 3D lumenized colonies (morphologically reminiscent of epiblasts). Unprecedented >275-fold amplification of hiPSCs within 6.5 days in 10L bioreactors, with high reproducibility and maintenance of...
GAIA BioMedicine, a Japan-based clinical-stage company pioneering allogeneic NK-like cell therapies against solid tumors, and TreeFrog Therapeutics, a global biotechnology company advancing a pipeline of cell therapies based on the biomimetic C-Stem™ technology platform, today announced they have entered into a collaboration for the expansion...
In the 2023, the webcast "In the Stem Cell Jungle" hosted by Maxime Feyeux, co-founder and CSO of TreeFrog Therapeutics becomes a blog. What will you find in the Stem Cell Jungle ? #1 Exclusive & free resources: a list of cell therapy trials based on pluripotent...
The whole team wishes you a Merry Christmas & Happy New Year !...
We had the chance to interview Teisha Rowland, Ph.D., Principal Scientist at Umoja Biopharma during the ISSCR in San Francisco about the Umoja/TreeFrog partnership. Leading iPSC engineering at Umoja, she comes back on the vision of Umoja, its RACR™ technology and her interest in TreeFrog's...
Bordeaux, France, Cambridge (MA), USA / October 20th, 2022 – TreeFrog Therapeutics, a biotechnology company aimed at making safer, more efficient and more affordable cell therapies based on induced pluripotent stem cells (iPSCs), today announced that an international team composed of 3 PhD students from King’s College...
The machine will be transferred in 2023 to a contract development and manufacturing organization (CDMO) to produce TreeFrog’s cell therapy candidate for Parkinson’s disease, with the aim of a first-in-human trial in 2024. Over 2023, Invetech will deliver three additional GMP encapsulation devices to support...
Bordeaux, France / August 30th, 2022 – TreeFrog Therapeutics, a biotechnology company aimed at making safer, more efficient and more affordable cell therapies based on induced pluripotent stem cells (iPSCs), today announced the nomination of 10 international scientists for the Stem Cell SpaceShot grant. Each...
Bordeaux, France / July 7th, 2022 – Peter Nell, Ph.D., was appointed independent board member of TreeFrog Therapeutics. Peter Nell led business development and corporate strategy activities in the cell & gene therapy field over the past ten years and is currently building a new...
We had the chance to interview Teisha Rowland, Ph.D., Principal Scientist at Umoja Biopharma during the ISSCR in San Francisco about the Umoja/TreeFrog partnership. Leading iPSC engineering at Umoja, she comes back on the vision of Umoja, its RACR™ technology and her interest in TreeFrog's...